Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Regulatory News (EVG)

  • There is currently no data for EVG

Form 8.5 (EPT/RI)

28 Oct 2011 10:46

RNS Number : 0417R
Bank of America Merrill Lynch
28 October 2011
 



FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH

RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

1. KEY INFORMATION

(a) Name of exempt principal trader: Bank of America Merrill Lynch

(b) Name of offeror/offeree in relation to whose INVESTEC LTD

relevant securities this form relates:

(c) Name of the party to the offer with which exempt Advisor to INVESTEC PLC and

INVESTEC LTD

principal trader is connected:

(d) Date dealing undertaken: 27/10/2011

(e) Has the EPT previously disclosed, or is it today NO

disclosing, under the Code in respect of any other

party to this offer?

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

(a) Purchases and sales

Class of Purchase/ Total number Highest price Lowest price

relevant Sales of securities per unit per unit

security paid/received paid/received

Common - ZAE000081949 Purchase 5,478 ZAR 50.25 ZAR 48.85

Common - ZAE000081949 Sale 5,478 ZAR 49.73 ZAR 49.73

(b) Derivatives transactions (other than options)

Class of Product  Nature of dealing Number of  Price per unit

relevant description reference securities

security

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Class of Product Writing, Number of Exercise Type Expiry Option

relevant description purchasing, securities price date money

security selling, to which per unit paid/

varying etc. option received

relates per unit

(ii) Exercising

Class of relevant Product description Number of securities Exercise price per unit

security

(d) Other dealings (including subscribing for new securities)

Class of relevant Nature of dealing Details Price per unit (if

security applicable)

3. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding,

formal or informal, relating to relevant securities which may be an inducement to deal

or refrain from dealing entered into by the exempt principal trader making the

disclosure and any party to the offer or any person acting in concert with a party to the

offer:

NONE

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between

the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which

any derivative is referenced:

NONE

Date of disclosure: 28/10/2011

Contact name: Balenkosi Dungeni

Telephone number: +44 20 7996 1639

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH

RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

1. KEY INFORMATION

(a) Name of exempt principal trader: Bank of America Merrill Lynch

(b) Name of offeror/offeree in relation to whose Evolution Group Plc

relevant securities this form relates:

(c) Name of the party to the offer with which exempt Advisor to INVESTEC PLC and

INVESTEC LTD

principal trader is connected:

(d) Date dealing undertaken: 27/10/2011

(e) Has the EPT previously disclosed, or is it today NO

disclosing, under the Code in respect of any other

party to this offer?

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

(a) Purchases and sales

Class of Purchase/ Total number Highest price Lowest price

relevant Sales of securities per unit per unit

security paid/received paid/received

Common - GB0030221864 Purchase 38,578 GBP 0.88 GBP 0.88

Common - GB0030221864 Sale 63,444 GBP 0.89 GBP 0.88

(b) Derivatives transactions (other than options)

Class of Product  Nature of dealing Number of  Price per unit

relevant description reference securities

security eg. CFD

Common - GB0030221864 Swap SHORT 15675 GBP 0.88

Common - GB0030221864 Swap SHORT 13747 GBP 0.88

Common - GB0030221864 Swap SHORT 8781 GBP 0.88

Common - GB0030221864 Swap SHORT 375 GBP 0.88

Class of Product  Nature of dealing Number of  Price per unit

relevant description reference securities

security eg. CFD

Common - GB0030221864 Swap LONG 658 GBP 0.88

Common - GB0030221864 Swap LONG 1707 GBP 0.88

Common - GB0030221864 Swap LONG 7074 GBP 0.89

Common - GB0030221864 Swap LONG 13747 GBP 0.88

Common - GB0030221864 Swap LONG 15017 GBP 0.89

Common - GB0030221864 Swap LONG 25241 GBP 0.88

 

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Class of Product Writing, Number of Exercise Type Expiry Option

relevant description purchasing, securities price date money

security selling, to which per unit paid/

varying etc. option received

relates per unit

(ii) Exercising

Class of relevant Product description Number of securities Exercise price per unit

security

(d) Other dealings (including subscribing for new securities)

Class of relevant Nature of dealing Details Price per unit (if

security applicable)

3. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding,

formal or informal, relating to relevant securities which may be an inducement to deal

or refrain from dealing entered into by the exempt principal trader making the

disclosure and any party to the offer or any person acting in concert with a party to the

offer:

NONE

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between

the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which

any derivative is referenced:

NONE

Date of disclosure: 28/10/2011

Contact name: Doug Berwick

Telephone number: +44 20 7995 8859

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH

RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

1. KEY INFORMATION

(a) Name of exempt principal trader: Bank of America Merrill Lynch

(b) Name of offeror/offeree in relation to whose INVESTEC PLC

relevant securities this form relates:

(c) Name of the party to the offer with which exempt Advisor to INVESTEC PLC and

INVESTEC LTD

principal trader is connected:

(d) Date dealing undertaken: 27/10/2011

(e) Has the EPT previously disclosed, or is it today NO

disclosing, under the Code in respect of any other

party to this offer?

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

(a) Purchases and sales

Class of Purchase/ Total number Highest price Lowest price

relevant Sales of securities per unit per unit

security paid/received paid/received

Common - GB00B17BBQ50 Purchase 26,818 GBP 3.97 GBP 3.81

Common - GB00B17BBQ50 Sale 17,309 GBP 3.98 GBP 3.89

(b) Derivatives transactions (other than options)

Class of Product  Nature of dealing Number of  Price per unit

relevant description reference securities

security eg. CFD

Common - Swap SHORT 7448 GBP 3.97

Common - Swap SHORT 5300 GBP 3.96

Common - Swap SHORT 2767 GBP 3.93

Common - Swap SHORT 2551 GBP 3.81

Common - Swap SHORT 1285 GBP 3.97

Common - Swap SHORT 1097 GBP 3.93

Common - Swap SHORT 1026 GBP 3.97

Common - Swap SHORT 481 GBP 3.94

Common - Swap SHORT 242 GBP 3.97

Common - Swap SHORT 200 GBP 3.89 Common - Swap SHORT 400 GBP 3.92 Common - Swap SHORT 548 GBP 3.96

 

 

Class of Product  Nature of dealing Number of  Price per unit

relevant description reference securities

security eg. CFD

Common - Swap LONG 48 GBP 3.98

Common - Swap LONG 2210 GBP 3.98

Common - Swap LONG 2432 GBP 3.89

Common - Swap LONG 2619 GBP 3.95

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Class of Product Writing, Number of Exercise Type Expiry Option

relevant description purchasing, securities price date money

security selling, to which per unit paid/

varying etc. option received

relates per unit

(ii) Exercising

Class of relevant Product description Number of securities Exercise price per unit

security

(d) Other dealings (including subscribing for new securities)

Class of relevant Nature of dealing Details Price per unit (if

security applicable)

3. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding,

formal or informal, relating to relevant securities which may be an inducement to deal

or refrain from dealing entered into by the exempt principal trader making the

disclosure and any party to the offer or any person acting in concert with a party to the

offer:

NONE

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between

the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which

any derivative is referenced:

NONE

Date of disclosure: 28/10/2011

Contact name: Doug Berwick

Telephone number: +44 20 7995 8859

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FERKVLBLFBFZFBF
Date   Source Headline
10th Oct 202211:05 amRNSSecond Price Monitoring Extn
10th Oct 202211:00 amRNSPrice Monitoring Extension
10th Oct 20227:00 amRNSSFX-01 licensing deal for up to $160.5m
29th Sep 20227:00 amRNSRegulatory approval for healthy volunteer study
22nd Jul 20227:00 amRNSResult of AGM
14th Jul 202212:43 pmRNSInvestor Presentation
6th Jul 202212:25 pmRNSNotice of AGM
13th Jun 20227:00 amRNSCollaboration with University of Michigan
8th Jun 20227:00 amRNSFull Year Results
7th Jun 20227:00 amRNSNotice of Results
25th May 20227:00 amRNSCollaboration with Università Sapienza di Roma
29th Apr 20222:39 pmRNSHolding(s) in Company
15th Mar 20222:05 pmRNSSecond Price Monitoring Extn
15th Mar 20222:00 pmRNSPrice Monitoring Extension
7th Mar 20227:00 amRNSManchester Breast Centre collaboration expanded
18th Jan 20227:00 amRNSOption over new sulforaphane analogues
11th Jan 20227:00 amRNSProgress with UK and US regulators for 2022 trials
30th Dec 202111:35 amRNSHolding(s) in Company
8th Dec 20212:08 pmRNSGrant of Options
7th Dec 20217:00 amRNSHalf-year Report
23rd Nov 20217:00 amRNSNotice of Results
10th Nov 20217:00 amRNSPublication of data on SFX-01 in glioblastoma
19th Oct 20212:39 pmRNSHolding(s) in Company
20th Sep 20217:00 amRNSPublication of data in glioblastoma cells
2nd Sep 20212:32 pmRNSHolding(s) in Company
2nd Sep 20212:06 pmRNSSecond Price Monitoring Extn
2nd Sep 20212:00 pmRNSPrice Monitoring Extension
2nd Sep 202111:05 amRNSSecond Price Monitoring Extn
2nd Sep 202111:01 amRNSGlioma Orphan Drug designation granted by FDA
2nd Sep 202111:00 amRNSPrice Monitoring Extension
25th Aug 20214:42 pmRNSHolding(s) in Company
24th Aug 20214:41 pmRNSSecond Price Monitoring Extn
24th Aug 20214:36 pmRNSPrice Monitoring Extension
9th Aug 20215:06 pmRNSHolding(s) in Company
20th Jul 202111:57 amRNSHolding(s) in Company
16th Jul 20211:50 pmRNSHolding(s) in Company
14th Jul 202110:23 amRNSHolding(s) in Company
13th Jul 20215:02 pmRNSResult of AGM and Business Update
13th Jul 20213:55 pmRNSHolding(s) in Company
13th Jul 20217:00 amRNSEarly data for SFX-01 in leukaemia cell lines
13th Jul 20217:00 amRNSGlioma Orphan Drug application submitted to US FDA
9th Jul 202111:05 amRNSSecond Price Monitoring Extn
9th Jul 202111:00 amRNSPrice Monitoring Extension
9th Jul 20217:00 amRNSInterim Safety and Futility Analysis - STAR trial
18th Jun 20217:00 amRNSPosting of Annual Report and Notice of AGM
15th Jun 20217:00 amRNSFinal Results
14th Jun 20217:00 amRNSProgress on metastatic breast cancer programme
14th Jun 20217:00 amRNSProgress with Glioma/Glioblastoma programme
26th Apr 20217:00 amRNSAppointment of Chief Medical Officer
7th Apr 20217:00 amRNSPublication on sulforaphane in COVID-19

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.